High-Throughput Discovery of Synergistic Drug Combinations for Metastatic Colorectal Cancer

高通量发现转移性结直肠癌的协同药物组合

• 批准号: nhmrc : 1079362
• 负责人: A/Pr Ian Street
• 金额: $ 101.79万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2015
• 资助国家: 澳大利亚
• 起止时间: 2015-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/high-throughput-discovery-colorectal-cancer/518658
• 关键词: Throughput; Discovery; Synergistic; Drug; Combinations

Treatment outcomes for patients with metastatic bowel cancer remain poor, with most tumours developing resistance within 24 months. A key problem is that cancers are genetically diverse, with some cells inevitably resistant to any given treatment. This study aims to discover effective drug combinations targeting distinct essential tumour cell functions through robotics-based pairwise testing of known drugs on bowel cancer cell lines representing the genetic diversity of the disease.

转移性肠癌患者的治疗结果仍然很差，大多数肿瘤在24个月内产生耐药性。一个关键的问题是，癌症在遗传上是多样化的，一些细胞不可避免地对任何特定的治疗产生抗药性。这项研究旨在通过对代表该疾病遗传多样性的肠癌细胞系进行基于机器人的已知药物成对测试，发现针对不同基本肿瘤细胞功能的有效药物组合。